HCWB logo

HCW Biologics (HCWB) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 July 2021

Indexes:

Not included

Description:

HCW Biologics (HCWB) focuses on developing innovative biologic therapies for various diseases. The company specializes in creating advanced treatments using biological materials, aiming to improve patient outcomes and enhance healthcare solutions. Their research emphasizes safety, efficacy, and accessibility in the biopharmaceutical industry.

Events Calendar

Earnings

Next earnings date:

Apr 01, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Apr 01, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

19 Apr '23 EF Hutton
Buy
30 Mar '23 EF Hutton
Buy
23 Mar '23 EF Hutton
Buy
08 Nov '22 JonesTrading
Buy
24 Mar '22 Maxim Group
Buy
19 Nov '21 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
HCWB
globenewswire.com14 November 2024

MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024.

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
HCWB
globenewswire.com23 August 2024

This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla.

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
HCWB
globenewswire.com14 August 2024

MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024.

FAQ

  • What is the primary business of HCW Biologics?
  • What is the ticker symbol for HCW Biologics?
  • Does HCW Biologics pay dividends?
  • What sector is HCW Biologics in?
  • What industry is HCW Biologics in?
  • What country is HCW Biologics based in?
  • When did HCW Biologics go public?
  • Is HCW Biologics in the S&P 500?
  • Is HCW Biologics in the NASDAQ 100?
  • Is HCW Biologics in the Dow Jones?
  • When was HCW Biologics's last earnings report?
  • When does HCW Biologics report earnings?
  • Should I buy HCW Biologics stock now?

What is the primary business of HCW Biologics?

HCW Biologics (HCWB) focuses on developing innovative biologic therapies for various diseases. The company specializes in creating advanced treatments using biological materials, aiming to improve patient outcomes and enhance healthcare solutions. Their research emphasizes safety, efficacy, and accessibility in the biopharmaceutical industry.

What is the ticker symbol for HCW Biologics?

The ticker symbol for HCW Biologics is NASDAQ:HCWB

Does HCW Biologics pay dividends?

No, HCW Biologics does not pay dividends

What sector is HCW Biologics in?

HCW Biologics is in the Healthcare sector

What industry is HCW Biologics in?

HCW Biologics is in the Biotechnology industry

What country is HCW Biologics based in?

HCW Biologics is headquartered in United States

When did HCW Biologics go public?

HCW Biologics's initial public offering (IPO) was on 20 July 2021

Is HCW Biologics in the S&P 500?

No, HCW Biologics is not included in the S&P 500 index

Is HCW Biologics in the NASDAQ 100?

No, HCW Biologics is not included in the NASDAQ 100 index

Is HCW Biologics in the Dow Jones?

No, HCW Biologics is not included in the Dow Jones index

When was HCW Biologics's last earnings report?

HCW Biologics's most recent earnings report was on 14 November 2024

When does HCW Biologics report earnings?

The next expected earnings date for HCW Biologics is 1 April 2025

Should I buy HCW Biologics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions